Can a phone call uncover missed cognitive decline? CaringAI’s AAIC data offer an early answer
CaringAI’s phone-based cognitive screening matched clinician scoring in a small study, but larger validation will determine its clinical reach.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
C2N Diagnostics gains Anthem coverage for PrecivityAD2 blood-based Alzheimer’s evaluation
Anthem will cover C2N Diagnostics’ PrecivityAD2 from October 2026. Read what the move means for Alzheimer’s blood testing access.
Medical Devices & Diagnostics
Grey Matters Health targets Alzheimer’s imaging bottleneck with dedicated PET clinic
Grey Matters Health’s planned NovaScan clinic in Florida will use the CareMiBrain dedicated PET system to expand access to amyloid imaging, while testing whether specialist neuroimaging can become a scalable outpatient service.
Pharma & Biotech
Alzheon builds oral Alzheimer’s case around brain microstructure and lower ARIA risk
Explore how Alzheon’s new valiltramiprosate brain and safety data could reshape oral Alzheimer’s treatment after a Phase 3 setback.
Pharma & Biotech
Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
Find out how Elixiron’s enrupatinib Phase 2 data could reshape Alzheimer’s neuroinflammation research and what risks remain.
Pharma & Biotech
Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Pharma & Biotech
Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Features & Analysis
Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Pharma & Biotech
Why Fosun Pharma’s AriBio deal could reshape the race for oral Alzheimer’s therapies
Alzheimer’s drugs are moving beyond antibodies. Fosun Pharma’s AR1001 option turns one Phase 3 readout into a global commercial test.
Medical Devices & Diagnostics
Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking
Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.